Squarepoint Ops LLC Has $10.89 Million Holdings in Avalo Therapeutics, Inc. $AVTX

Key Points

• Institutional ownership surged: Squarepoint Ops increased its Avalo Therapeutics stake by 624.9% to 589,245 shares valued at $10.89 million. Institutional investors and hedge funds collectively own 87.06% of AVTX.
• Analysts remain broadly bullish: Twelve analysts rate the stock Buy versus one Sell, producing a “Moderate Buy” consensus and an average price target of $45.10, despite some target revisions.
• Recent results missed expectations: Avalo reported a quarterly loss of $0.83 per share, wider than the $0.58 consensus estimate. Shares opened at $18.21, while analysts expect a full-year loss of $2.69 per share.

Squarepoint Ops LLC grew its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 624.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 589,245 shares of the company's stock after purchasing an additional 507,960 shares during the quarter. Squarepoint Ops LLC owned approximately 1.10% of Avalo Therapeutics worth $10,889,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. UBS Group AG boosted its holdings in Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company's stock worth $8,677,000 after buying an additional 432,608 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company's stock valued at $1,793,000 after acquiring an additional 101,814 shares during the last quarter. Seven Fleet Capital Management LP raised its position in shares of Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company's stock valued at $8,568,000 after acquiring an additional 510,540 shares during the period. DV Trading LLC acquired a new stake in shares of Avalo Therapeutics in the 1st quarter valued at approximately $5,376,000. Finally, Sei Investments Co. bought a new position in Avalo Therapeutics during the 1st quarter worth approximately $849,000. Institutional investors and hedge funds own 87.06% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AVTX. Citizens Jmp decreased their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Thursday, May 14th. Mizuho lifted their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, May 14th. BTIG Research reissued a "buy" rating and issued a $58.00 price target on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an "outperform" rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $45.10.

Avalo Therapeutics Price Performance

AVTX opened at $18.21 on Thursday. The business's 50-day moving average price is $19.16 and its two-hundred day moving average price is $17.04. Avalo Therapeutics, Inc. has a 1 year low of $9.54 and a 1 year high of $24.27. The company has a market capitalization of $976.60 million, a price-to-earnings ratio of -4.17 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). Sell-side analysts anticipate that Avalo Therapeutics, Inc. will post -2.69 earnings per share for the current fiscal year.

Insider Transactions at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the business's stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider directly owned 51,776 shares of the company's stock, valued at $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 3,129 shares of company stock valued at $59,680. 4.46% of the stock is currently owned by insiders.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.